Literature DB >> 16882704

CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent.

Luca Gattinoni1, Anju Ranganathan, Deborah R Surman, Douglas C Palmer, Paul A Antony, Marc R Theoret, David M Heimann, Steven A Rosenberg, Nicholas P Restifo.   

Abstract

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) maintains peripheral tolerance by suppressing T-cell activation and proliferation but its precise role in vivo remains unclear. We sought to elucidate the impact of CTLA-4 expression on self/tumor-reactive CD8(+) T cells by using the glycoprotein (gp) 100-specific T-cell receptor (TCR) transgenic mouse, pmel-1. pmel-1 CLTA-4(-/-) mice developed profound, accelerated autoimmune vitiligo. This enhanced autoimmunity was associated with a small but highly activated CD8(+) T-cell population and large numbers of CD4(+) T cells not expressing the transgenic TCR. Adoptive transfer of pmel-1 CLTA-4(-/-) CD8(+) T cells did not mediate superior antitumor immunity in the settings of either large established tumors or tumor challenge, suggesting that the mere absence of CTLA-4-mediated inhibition on CD8(+) T cells did not directly promote enhancement of their effector functions. Removal of CD4(+) T cells by crossing the pmel-1 CLTA-4(-/-) mouse onto a Rag-1(-/-) background resulted in the complete abrogation of CD8(+) T-cell activation and autoimmune manifestations. The effects of CD4(+) CLTA-4(-/-) T cells were dependent on the absence of CTLA-4 on CD8(+) T cells. These results indicated that CD8(+) CLTA-4(-/-) T-cell-mediated autoimmunity and tumor immunity required CD4(+) T cells in which the function was dysregulated by the absence of CTLA-4-mediated negative costimulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16882704      PMCID: PMC1679662          DOI: 10.1182/blood-2006-07-034066

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression.

Authors:  Brigitte Birebent; Richard Lorho; Hélène Lechartier; Sophie de Guibert; Mehdi Alizadeh; Nicolas Vu; Alain Beauplet; Nelly Robillard; Gilbert Semana
Journal:  Eur J Immunol       Date:  2004-12       Impact factor: 5.532

2.  Molecular basis of T cell inactivation by CTLA-4.

Authors:  K M Lee; E Chuang; M Griffin; R Khattri; D K Hong; W Zhang; D Straus; L E Samelson; C B Thompson; J A Bluestone
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

Review 3.  The emerging role of CTLA-4 as an immune attenuator.

Authors:  C B Thompson; J P Allison
Journal:  Immunity       Date:  1997-10       Impact factor: 31.745

4.  In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance.

Authors:  E M Sotomayor; I Borrello; E Tubb; J P Allison; H I Levitsky
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

5.  CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

Authors:  Sergio A Quezada; Karl S Peggs; Michael A Curran; James P Allison
Journal:  J Clin Invest       Date:  2006-06-15       Impact factor: 14.808

6.  Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.

Authors:  A van Elsas; A A Hurwitz; J P Allison
Journal:  J Exp Med       Date:  1999-08-02       Impact factor: 14.307

7.  Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses.

Authors:  C A Chambers; M S Kuhns; J P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

8.  Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous.

Authors:  M F Bachmann; G Köhler; B Ecabert; T W Mak; M Kopf
Journal:  J Immunol       Date:  1999-08-01       Impact factor: 5.422

9.  Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells.

Authors:  C A Chambers; T J Sullivan; T Truong; J P Allison
Journal:  Eur J Immunol       Date:  1998-10       Impact factor: 5.532

10.  Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help.

Authors:  K D McCoy; I F Hermans; J H Fraser; G Le Gros; F Ronchese
Journal:  J Exp Med       Date:  1999-04-05       Impact factor: 14.307

View more
  26 in total

Review 1.  Inhibitory costimulation and anti-tumor immunity.

Authors:  Natalia Martin-Orozco; Chen Dong
Journal:  Semin Cancer Biol       Date:  2007-06-23       Impact factor: 15.707

2.  A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.

Authors:  Theodore S Nowicki; Beata Berent-Maoz; Gardenia Cheung-Lau; Rong Rong Huang; Xiaoyan Wang; Jennifer Tsoi; Paula Kaplan-Lefko; Paula Cabrera; Justin Tran; Jia Pang; Mignonette Macabali; Ivan Perez Garcilazo; Ignacio Baselga Carretero; Anusha Kalbasi; Alistair J Cochran; Catherine S Grasso; Siwen Hu-Lieskovan; Bartosz Chmielowski; Begoña Comin-Anduix; Arun Singh; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2018-12-20       Impact factor: 12.531

Review 3.  Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.

Authors:  Katia Boniface; Julien Seneschal; Mauro Picardo; Alain Taïeb
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 4.  New approaches for the immunotherapy of acute myeloid leukemia.

Authors:  Terrence L Geiger; Jeffrey E Rubnitz
Journal:  Discov Med       Date:  2015-04       Impact factor: 2.970

5.  Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.

Authors:  Stefanie N Linch; Melissa J Kasiewicz; Michael J McNamara; Ian F Hilgart-Martiszus; Mohammad Farhad; William L Redmond
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-04       Impact factor: 11.205

Review 6.  At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Authors:  Andrew M Intlekofer; Craig B Thompson
Journal:  J Leukoc Biol       Date:  2013-04-26       Impact factor: 4.962

Review 7.  Modulation of CTLA-4 and GITR for cancer immunotherapy.

Authors:  Francesca Avogadri; Jianda Yuan; Arvin Yang; David Schaer; Jedd D Wolchok
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

8.  Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.

Authors:  William L Redmond; Stefanie N Linch; Melissa J Kasiewicz
Journal:  Cancer Immunol Res       Date:  2013-11-11       Impact factor: 11.151

9.  Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Authors:  Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2007-11-02       Impact factor: 12.531

10.  Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.

Authors:  Antoni Ribas; Begoña Comin-Anduix; Bartosz Chmielowski; Jason Jalil; Pilar de la Rocha; Tara A McCannel; Maria Teresa Ochoa; Elizabeth Seja; Arturo Villanueva; Denise K Oseguera; Bradley R Straatsma; Alistair J Cochran; John A Glaspy; Liu Hui; Francesco M Marincola; Ena Wang; James S Economou; Jesus Gomez-Navarro
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.